Entries by arcticnovartis

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
arcticnovartis
Tue, 04/23/2024 – 07:04

Read more about Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidan…

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
arcticnovartis
Wed, 04/17/2024 – 07:19

Read more about Novartis Kesimpta® six-year efficacy data sh…

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
arcticnovartis
Mon, 04/15/2024 – 20:04

Read more about New Nova…

Novartis tender offer for MorphoSys AG commences

Novartis tender offer for MorphoSys AG commences
arcticnovartis
Thu, 04/11/2024 – 10:24

Read more about Novartis tender offer for MorphoSys AG commences

Basel, April 11, 2024 – Novartis published today the offer document for the vo…

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
arcticnovartis
Sat, 04/06/2024 – 22:19

Read more about New…

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
arcticnovartis
Fri, 03/22/2024 – 12:34

Read more about Novartis Fabhalta® (iptacopan) receives…

Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut

Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
arcticnovartis
Tue, 03/05/2024 – 15:34

Read more about Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen…

Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire

Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
arcticnovartis
Tue, 03/05/2024 – 15:34

Read more about Les actionnaires de Novartis approuvent toutes le…

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
arcticnovartis
Tue, 03/05/2024 – 15:34

Read more about Novartis shareholders approve all resolutions proposed by the Board of Directors a…

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
arcticnovartis
Mon, 03/04/2024 – 07:19

Read more about Novartis presents new data on safety an…